Core Insights - Bausch + Lomb reported a GAAP revenue growth of 5% year over year to $1.278 billion, exceeding analyst expectations by $18 million [1] - Adjusted EPS (non-GAAP) was $0.07, beating consensus estimates by $0.01 but down 46.2% from $0.13 in the previous year [2] - The company experienced a narrowed net loss of $62 million compared to $151 million a year earlier, indicating some operational improvement [2][8] Business Overview - Bausch + Lomb specializes in eye health products, including contact lenses, OTC consumer eye care brands, prescription pharmaceuticals, and surgical devices, operating in three segments: Vision Care, Surgical, and Pharmaceuticals [3] Strategic Focus - The growth strategy includes a broad product portfolio, separation from Bausch Health Companies, geographic expansion, and investment in R&D, while managing regulatory risks and increasing scale in consumer and surgical markets [4] Quarterly Performance - Vision Care segment revenue reached $753 million, up 8% year over year, driven by daily silicone hydrogel contact lenses and consumer brands [5] - Surgical segment revenue was $216 million, growing 3% year over year, despite a voluntary recall of certain enVista IOL products [6] - Pharmaceuticals revenue declined to $309 million, attributed to weak US generics performance and pricing pressures [7] Profitability Metrics - Adjusted EBITDA (non-GAAP) decreased to $191 million, reflecting higher spending on marketing and costs from the recall [8] - Cash flow from operations improved to $35 million, a 133.3% increase from the previous year, due to better working capital management [2][8] Research and Development - R&D expenses increased to $96 million, with around 60 projects underway, including next-generation contact lenses and therapeutics for glaucoma and dry eye disease [9] Future Guidance - Full-year 2025 revenue guidance was raised to $5.05 billion to $5.15 billion, with projected constant currency revenue growth between 5% and 7% [10] - Adjusted EBITDA guidance for 2025 is set at $860 million to $910 million, driven by demand in Vision Care and Surgical [10] Key Watch Points - Management highlighted potential tariff impacts on adjusted EBITDA margin, estimating a 120 basis point headwind in the second half of 2025 [11] - Ongoing cost control, stabilization of Pharmaceuticals, and new product rollouts in Vision Care and Surgical are critical areas to monitor [11]

Core Insights - Merit Medical reported revenue of $382.46 million for the quarter ended June 2025, reflecting a 13.2% increase year-over-year, with EPS at $1.01 compared to $0.92 in the previous year [1] - The reported revenue met the Zacks Consensus Estimate, while the EPS exceeded the consensus estimate by 17.44% [1] Financial Performance Metrics - U.S. sales reached $227.08 million, surpassing the estimated $220.3 million, marking a 16.7% increase from the same quarter last year [4] - International sales amounted to $155.38 million, exceeding the estimated $151.04 million, representing an 8.4% year-over-year growth [4] - Revenue from Cardiovascular-Peripheral Intervention was $142.85 million, slightly below the estimated $144.62 million, with a year-over-year increase of 2.6% [4] - Cardiovascular-Cardiac Intervention revenue was $115.25 million, exceeding the estimated $104.93 million, showing a significant 22.8% increase year-over-year [4] - Endoscopy revenue reached $18.44 million, slightly below the estimated $18.66 million, but reflecting an impressive 81% increase from the previous year [4] - Cardiovascular-OEM revenue was $52.29 million, close to the estimated $52.65 million, with an 18.1% year-over-year increase [4] - Total Cardiovascular revenue was $364.03 million, surpassing the estimated $353.56 million, indicating an 11.1% increase year-over-year [4] - Revenue from Cardiovascular-Custom Procedural Solutions was $53.63 million, exceeding the estimated $51.05 million, with a year-over-year growth of 6.4% [4] Stock Performance - Merit Medical's shares have declined by 11.8% over the past month, contrasting with a 3.4% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Press release Ecully, July 30, 2025 – 7 p.m. SPINEWAY H1 2025 results Continued improvement in results and financial positionFull-year 2025 growth target confirmed In thousands of eurosConsolidated financial statements – UnauditedH1 2025H1 2024Revenue5,5736,535Cost of sales(1,702)(2,059)<td style="vertical-align: middle; text-align: left; padding-left: 15.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom ...

Core Insights - Sanmina Corporation (SANM) reported strong third-quarter fiscal 2025 results, with both revenue and net income exceeding the Zacks Consensus Estimate [1][2][3] Financial Performance - Net income on a GAAP basis was $68.6 million or $1.26 per share, up from $51.6 million or 91 cents per share in the prior-year quarter [2] - Non-GAAP net income was $83.6 million or $1.53 per share, compared to $70.8 million or $1.25 in the prior-year quarter, surpassing the Zacks Consensus Estimate of $1.42 [2] - Net sales increased to $2.04 billion from $1.84 billion year over year, beating the consensus estimate by $67 million [3] Segment Performance - Integrated Manufacturing Solutions generated $1.64 billion in revenues, an 11.6% increase year over year, contributing 80.7% to total revenues [4] - Components, Products and Services revenues rose to $422 million, up 8.8% year over year [4] - Industrial & Energy, Medical, Defense & Aerospace, and Automotive markets generated $1.256 billion in revenues, a 6.2% increase year over year [5] - Communications Networks and Cloud Infrastructure generated $786 million, up 19.2% year over year [5] Profitability Metrics - Non-GAAP gross profit was $186 million, compared to $157 million in the year-ago quarter, driven by a favorable mix and improved operational efficiency [6] - Non-GAAP operating income totaled $115.7 million, up from $96.8 million in the prior-year period, with a non-GAAP operating margin of 5.7%, slightly up from 5.3% [6] Cash Flow and Liquidity - Generated $200.8 million of net cash from operating activities, compared to $90 million in the previous year's quarter [7] - As of June 28, 2025, the company had $797.9 million in cash and cash equivalents and $287.2 million in long-term debt [7] - The company repurchased approximately 0.2 million shares for about $13 million during the quarter [7] Outlook - For the fourth quarter of fiscal 2025, revenues are expected to be in the range of $2-$2.1 billion, with GAAP earnings per share forecasted between $1.21 and $1.31 [10] - Management estimates non-GAAP earnings per share in the band of $1.52-$1.62 [10]

Financial Data and Key Metrics Changes - VITAS net revenue was $396.2 million in 2025, an increase of 5.8% compared to the prior year period, driven by a 6.1% increase in days of care and a 4.2% increase in Medicare reimbursement rates [12] - Adjusted EBITDA excluding Medicare Cap totaled $66.8 million in the quarter, essentially flat with 2024, with an adjusted EBITDA margin of 16.2%, down 163 basis points from the prior year [15][16] - Roto Rooter revenue increased by 6% in 2025 compared to the same period in 2024, falling short of internal expectations [8] Business Line Data and Key Metrics Changes - Admissions at DITAS totaled 17,545, a 1.2% improvement from the same period in 2024, with a 4.9% increase when excluding patient transfers from VITAS [5] - Roto Rooter branch residential revenue totaled $156.4 million, a 9% increase from the prior year, driven by a 16.9% increase in water restoration [17] - Roto Rooter branch commercial revenue totaled $53.2 million, a 4.4% increase from the prior year, with a 24.4% increase in excavation revenue [17] Market Data and Key Metrics Changes - Hospital-directed admissions increased by 9.1%, while home-based patient admissions declined by 6.2%, nursing home admissions declined by 2.9%, and assisted living facilities admissions declined by 1.4% compared to the prior year [6] - The consolidated Florida program is estimated to end the 2025 Medicare cap year with a $19 million billing limitation, with management expecting no significant Medicare cap billing limitation for the 2026 cap year [6][7] Company Strategy and Development Direction - The company remains confident in the growth potential and strategic direction of both businesses despite underperformance in 2025 [5] - VITAS is adjusting its patient mix in Florida to mitigate Medicare cap issues, which may cause some disruption in operating metrics but is expected to lead to higher growth rates in the long term [10] - Roto Rooter is focusing on improving its competitive advantages to return to a steadier growth trajectory [11] Management's Comments on Operating Environment and Future Outlook - Management commented on the impact of the Liberation Day tariff announcement on consumer confidence and spending, which affected Roto Rooter's performance in April and May [9] - The company is optimistic about the overall prospects for both businesses, with VITAS working on initiatives to improve admissions and Roto Rooter focusing on enhancing its service offerings [10][11] Other Important Information - The company estimates $28.2 million in Medicare cap billing limitations for calendar 2025, with $19 million related to the Florida combined program [23] - Roto Rooter's adjusted EBITDA totaled $48.6 million, a decrease of 18.7% compared to the prior year quarter, with a margin of 21.8% [18] Q&A Session Summary Question: Impact of Medicare cap and future margins - Management discussed the levers being pulled to ensure no carryover impact from the Medicare cap after Q3, emphasizing hospital admissions and the moderation of the patient mix bubble created by the Community Access Program [28][29] Question: Factors driving underperformance in admissions - Management noted that the increase in admissions was intentionally moderated to avoid providing services without reimbursement, focusing on hospital admissions instead [38][40] Question: Roto Rooter management issues and recovery - Management indicated that local management issues have been resolved, and the recovery seen in June and July is attributed to improved operational performance rather than management changes [49][50] Question: Tax rate favorability in Q2 - The decline in the effective tax rate was attributed to accounting factors related to stock option exercises, with fewer exercises in the quarter leading to a larger tax deduction [65][66] Question: Confidence in short stay patient mix - Management expressed confidence in achieving a higher mix of short stay patients through improved operational emphasis and reputation [70][71] Question: Capital deployment and acquisition strategy - The company remains open to acquisitions at the right valuation and location, with no change in strategy despite current business challenges [98]

Financial Data and Key Metrics Changes - VITAS net revenue was $396.2 million in Q2 2025, representing a 5.8% increase compared to the prior year period, driven by a 6.1% increase in days of care and a 4.2% increase in Medicare reimbursement rates [13][14] - Adjusted EBITDA excluding Medicare Cap totaled $66.8 million in the quarter, essentially flat with 2024, with an adjusted EBITDA margin of 16.2%, down 163 basis points from the prior year [16][17] - Roto Rooter revenue increased 6% in 2025 compared to the same period in 2024, falling short of internal expectations [8][9] Business Line Data and Key Metrics Changes - DITAS admissions totaled 17,545, a 1.2% improvement from the same period in 2024, with a 4.9% increase when excluding patient transfers to VITAS [5][6] - Roto Rooter branch residential revenue was $156.4 million, a 9% increase from the prior year, driven by a 16.9% increase in water restoration [20] - Roto Rooter adjusted EBITDA decreased by 18.7% to $48.6 million, with an adjusted EBITDA margin of 21.8%, reflecting inefficiencies in the labor force due to lower residential revenues [21][22] Market Data and Key Metrics Changes - Hospital-directed admissions increased by 9.1%, while home-based patient admissions declined by 6.2%, nursing home admissions declined by 2.9%, and assisted living facilities admissions declined by 1.4% compared to the prior year [6][10] - The consolidated Florida program is projected to end the 2025 Medicare cap year with a $19 million billing limitation, with management expecting no significant Medicare cap billing limitation for the 2026 cap year [6][7] Company Strategy and Development Direction - The company remains confident in the growth potential and strategic direction of both businesses despite underperformance in Q2 2025 [5][11] - VITAS is adjusting its patient mix in Florida to mitigate Medicare cap issues, which may cause some disruption in operating metrics but positions the company for long-term growth [11][12] - Roto Rooter is focusing on improving its competitive advantages and is optimistic about returning to a steadier growth trajectory [11][12] Management's Comments on Operating Environment and Future Outlook - Management noted that the weak admissions in April and May were influenced by external factors affecting consumer confidence and spending [10][11] - The company is optimistic about the overall prospects for both businesses, with VITAS management actively reviewing expenses to offset lower EBITDA margins [17][21] - Management expects to update assumptions regarding rates and the overall outlook for the 2026 Medicare cap year in the third quarter earnings release [7][26] Other Important Information - The company estimates $28.2 million in Medicare cap billing limitations for calendar 2025, with no limitations expected in the fourth quarter related to the Florida combined program [26] - Roto Rooter is forecasted to have a revenue increase of 1.25% to 1.75% in 2025 compared to 2024, with an adjusted EBITDA margin expected to be 23.5% to 24.5% [27] Q&A Session Summary Question: What measures are being taken to avoid Medicare cap issues in 2026? - Management emphasized hospital admissions and the moderation of the patient mix bubble created by the Community Access Program as key levers to avoid cap issues [31][32] Question: What is the outlook for admissions and revenue growth? - Management indicated that while admissions were slightly below expectations, they are confident in achieving a higher mix of short-stay patients moving forward [70][72] Question: How are local management issues affecting Roto Rooter's recovery? - Management stated that past local management issues have been resolved, and the focus is now on improving conversion rates and addressing market challenges [51][56] Question: What is the impact of the recent tax rate changes? - The effective tax rate decline was attributed to accounting factors related to stock option exercises, which are not expected to persist [67][68] Question: Is there a change in the company's acquisition strategy? - The company remains open to acquisitions at the right valuation and location, with no change in overall strategy despite current challenges [100][102]

Welcome back to the exchange. Spotify shares sinking today, down 10% right now after Q2 revenue miss lackluster guidance. My next guest recently upgraded shares to outperform and is establishing an $800 price tag.It's currently trading at $629 and change. Joining me now is Jason Hstein, head of internet research at Oenheimer. Jason, it's great to have you on.You upgraded the stock what last week ahead of the print today. What do you think now that we got these results. >> Correct.So our thought was the stoc ...

Core Insights - CBRE Group Inc. reported second-quarter 2025 core earnings per share (EPS) of $1.19, exceeding the Zacks Consensus Estimate of $1.05, and reflecting a year-over-year increase of 46.9% [1][9] - The company's shares rose over 8% following the earnings report, driven by strong revenue growth across most business segments, except for Real Estate Investments [2][9] - Total revenues for the quarter increased by 16.2% year over year to $9.75 billion, surpassing the Zacks Consensus Estimate of $9.37 billion [2][9] Revenue Breakdown - Adjusted net revenues rose 14% (12.9% in local currency) year over year to $5.67 billion, with core EBITDA increasing by 30.3% (28.9% in local currency) to $658 million [3] - The Advisory Services segment saw a revenue increase of 14.4% (13.8% in local currency) to $2 billion, while global leasing revenue grew by 14% (13% in local currency) [4] - Global property sales revenues grew by 20% (19% in local currency), with notable growth in the U.S. (25%), APAC (24%), and EMEA (19%) [5] - The Building Operations & Experience segment reported an 18.7% (17.5% in local currency) revenue increase to $5.76 billion, with facilities management revenues rising by 17% (16% in local currency) [6] Segment Performance - Project Management segment revenues increased by 14.3% (12.9% in local currency) to $1.79 billion, driven by growth from Turner & Townsend and CBRE's legacy business [7] - The Real Estate Investments segment experienced a revenue decline of 7.3% (9.1% in local currency) to $215 million [7] Financial Position - As of the end of Q2 2025, assets under management increased by $6.2 billion to $155.3 billion, aided by favorable foreign currency movements [8] - CBRE's cash and cash equivalents rose to $1.40 billion, with total liquidity increasing to $4.7 billion due to new financing activities [9][10] - The company's net leverage ratio was 1.47X, significantly below its primary debt covenant of 4.25X [10] Future Outlook - For 2025, CBRE raised its core EPS guidance to a range of $6.10-$6.20, compared to the previous guidance of $5.80-$6.10, with the Zacks Consensus Estimate currently at $5.94 [11]

Core Insights - Waste Connections, Inc. (WCN) reported strong second-quarter 2025 results, with earnings and revenues exceeding Zacks Consensus Estimates [1][2] - Despite the earnings beat, the stock price has not experienced significant movement since the results were released on July 23 [1] Financial Performance - Adjusted earnings per share were $1.29, surpassing the Zacks Consensus Estimate by 3.2% and reflecting a 4% year-over-year increase [2][9] - Revenues reached $2.4 billion, slightly beating consensus estimates and growing 7.1% from the previous year [2][9] - Year-to-date, WCN shares have increased by 8.4%, compared to the industry's 10.7% and the Zacks S&P 500 Composite's 8.2% growth [2] Segment Performance - The Solid Waste Collection segment generated revenues of $1.6 billion, which was below the estimated $1.7 billion [3] - The Solid Waste Disposal and Transfer segment saw a significant revenue increase of 71.1% year-over-year to $756 million, also missing projections [3] - The E&P Waste Treatment, Recovery and Disposal segment's revenues rose 4.9% to $123.6 million, falling short of the estimate [4] - The Solid Waste Recycling segment's revenues grew 3.5% to $63.3 million, missing the forecast [4] - The Intermodal and Other segment's revenues increased slightly to $49.1 million, also below expectations [4] Operating Results - Adjusted EBITDA for the quarter was $731.8 million, a decrease of 6.9% from the previous year, with an adjusted EBITDA margin of 32.6% [5] - Operating income was reported at $424.7 million, down from $459.5 million year-over-year [5] Balance Sheet & Cash Flow - At the end of Q2 2025, cash and cash equivalents stood at $62.4 million, down from $111.2 million in the previous quarter [6] - Long-term debt decreased to $8.1 billion from $8.4 billion [6] - Cash generated from operating activities was $611.4 million, with adjusted free cash flow at $402.6 million [7] - Capital expenditures totaled $217.2 million, and dividends paid amounted to $73.7 million [7] FY25 Outlook - For the full year 2025, Waste Connections expects revenues of $9.45 billion, which is below the Zacks Consensus Estimate of $9.51 billion [8][9] - Adjusted EBITDA is anticipated to be $3.12 billion, representing nearly 33% of total revenues [8]

Financial Performance - SoFi reports 44% year-over-year revenue growth to $858 million [2] - SoFi's operating margins are at 29% [2] - SoFi achieved a "rule of 40" score of 70, exceeding the benchmark [3] Business Strategy & Growth Drivers - SoFi's strategy is to be a one-stop shop across borrow, save, spend, invest, and protect [4] - Exceptional growth was seen across all three of SoFi's businesses [5] - SoFi is benefiting from unprecedented demand across all of its products [11] Investment & Market Perspective - SoFi is returning to crypto investing [1] - Investors are re-evaluating SoFi due to growth opportunities in AI, blockchain, and crypto [9][10] - SoFi's invest service offers a broad range of products, including single stocks, fractional shares, IPOs, ETFs, robo accounts, and alternative assets [7] Consumer Lending - Consumers are refinancing credit card debt with SoFi at lower interest rates (12-13% vs 24+%) [12] - SoFi is seeing a pickup in student loan refinancing [12] - SoFi money offers 38% interest with no fees [13]